Company Overview
About VenoStent
VenoStent is a Houston, Texas-based clinical-stage medical device company — backed by Y Combinator (W20) with $22.8 million in total funding including a $20 million Series A in June 2024 led by Good Growth Capital and IAG Capital Partners with $4 million from Norwest Venture Partners, plus a $3.6 million NIH SBIR Phase II Grant — developing SelfWrap, a bioabsorbable perivascular wrap designed to improve arteriovenous (AV) fistula patency rates for chronic kidney disease patients requiring hemodialysis access. Having initiated clinical sites and enrolled first patients in a 200-patient randomized controlled trial (RCT) across multiple US centers in 2024, VenoStent targets the 600,000+ American dialysis patients who depend on reliable vascular access as their lifeline.
Business Model & Competitive Advantage
VenoStent's SelfWrap perivascular device addresses the AV fistula failure rate that is the leading cause of hospitalization and morbidity in dialysis patients: an AV fistula (a surgical connection between an artery and vein in the forearm that creates a high-flow vascular access point for dialysis needle cannulation) fails to mature into a usable access in 20-60% of cases due to neointimal hyperplasia — the body's smooth muscle cell proliferation response to surgical trauma that narrows the vein and prevents adequate blood flow for dialysis. SelfWrap's bioabsorbable outer wrap (applied around the vein at the time of fistula creation, providing mechanical support and controlled drug delivery to modulate the healing response) is designed to reduce the hyperplasia cascade that causes fistula failure — improving the primary patency rates that determine whether a dialysis patient uses their own fistula or requires a catheter (which carries 3x higher infection risk and 2x higher mortality).
Competitive Landscape 2025–2026
In 2025, VenoStent competes in the hemodialysis vascular access, endovascular devices, and chronic kidney disease management market with Merit Medical (NASDAQ: MMSI, vascular access products, $1.2B revenue), BD (NYSE: BDX, hemodialysis catheter market leader, $20B revenue), and Vasc-Alert (AV access monitoring) for dialysis center and vascular surgery adoption of AV fistula maturation improvement devices. Good Growth Capital's Series A leadership and Norwest Venture Partners' participation reflect medtech venture conviction in vascular access innovation. NIH SBIR Phase II grant validation confirms scientific merit. Y Combinator W20 backing (unusual for a medical device company) connects VenoStent with the healthcare technology investor community. The 2025 strategy focuses on completing RCT enrollment across US dialysis and vascular surgery centers, building the clinical outcomes dataset for FDA De Novo or 510(k) submission, and engaging the dialysis network operators (DaVita, Fresenius) as commercial launch channels.
Recent Activity
View all →Key Differentiators
Strong Challenger
VenoStent is an established challenger with significant market presence and competitive offerings in Healthcare.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare VenoStent with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from VenoStent? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim VenoStent Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention VenoStent vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →